TitlePresentersAir Date
New Insights on Huntington’s Disease Age of Onset From Genetic Studies of HD FamiliesDr. James Gusella11/19/2019
DNA Repair in Huntington’s DiseaseDr. Tamara Maiuri02/20/2019
2018 Year in Review1/16/2019
RNAi-based huntingtin lowering in the central nervous system: a new potential HD therapeuticJulia Alterman10/18/2018
Update on Huntington’s Program and Clinical Trials from Roche/Genentech9/26/2018
Exercise for the brain and body the benefits of physical activity in Huntingtons5/25/18
Neural Stem Cells as a Therapeutic Candidate for Huntington’s DiseaseJack Reidling, PhD4/25/18
How can sheep help us develop huntingtin lowering therapies?Edith Pfister, MD3/21/2018
Selective Targeting of Mutant Huntingtin (mHTT) presented by Wave Life Sciences.2/7/2018
2017 Huntington’s Disease Research Year in Review Webinar1/17/2018
The SIGNAL Phase 2 Trial Clinical Development of VX15 Anti Semaphorin 4D Antibody as a potential treatment for HD9/17/2017
What’s the Deal with Neurofilament: A Blood Test that Predicts Huntington’s Disease Progression?Dr. Ed Wild & Lauren ByrneNovember 15, 2017
Interim Results from the Vaccinex SIGNAL TrialMaurice Zauderer9/19/17
Potential new drug target identified that could correct protein misfolding in Huntington’s diseaseDennis J. Thiele & Rocio Gomez-Pastor, Ph.DWed, Apr 5, 2017
2016 Year in Review2/1/17
PRIDE-HD Clinical Trial ResultsDr. Andrew McGarryWednesday, January 11th, 2017
Is HD More Prevalent Than Previously Thought?Chris Kay9/7/16
The FDA and Patient Engagement – What’s Next for the HD CommunityDr. John Whyte5/12/2016
PPAR delta is decreased in HD and can be targeted therapeuticallyAl LaSpada, MD, PhD4/28/2016
LEGATO-HD: A Clinical Study in Subjects with Huntington’s Disease to Assess the Efficacy and Safety of LaquinimodSpyros Papapetropoulos, MD, PhD2/3/16
The role of complement and synaptic loss in driving disease progression in Huntington’s diseaseDaniel Wilton, PhD3/16/16
2015: The Year in Review for HD ResearchGeorge Yohrling, PhD1/21/16
At Home Monitoring of Sleep/Wake Cycles in Huntington’s Disease PatientsDr. Dawn LohDecember 9, 2015
PF-02545920: An Investigational Pfizer Compound for the Treatment of Huntington’s DiseaseOttavio VitoloNovember 19, 2015
Genetic variation in huntingtin promoter as a bidirectional genetic modifier of Huntington’s diseaseDr. Kristina BecanovicOctober 7, 2015
The spread of mutant huntingtin protein from cell to cell and its implications for transplant therapies for Huntington’s diseaseFrancesca Cicchetti, PhDApril 16, 2015
Suppression of somatic expansion of CAG tract delays onset of disease in mouse model of HDHelen Budworth, PhDSeptember 16, 2015
Histone deacetylase (HDAC) inhibitors: assessing their potential for clinical use.Beth Thomas, PhDMarch 19, 2015
Stem Cells in HD Research and TherapeuticsJamshid Arjomand, PhDFebruary 27, 2013
Huntingtin ASOsHolly Kordasiewicz, PhDMarch 19, 2013
Sleep/Circadian Dysfunction in HDJenny Morton, PhD- University of CambridgeApril 24, 2013
Enroll-HDJoe Giuliano, CHDI FoundationMay 22, 2013
Kids-HD: Brain Imaging Research StudyPeg NopoulosJuly 24, 2013
Clinical Trials in Premanifest HD: Review of PREQUEL Results and Prospects for the FutureChris RossAugust 22, 2013
PDE10 Imaging in HD PatientsKen MarekSeptember 26, 2013
“FIRST-HD: A clinical Trial to test effectiveness of novel drug for reducing HD chorea”Sam Frank, MD and Claudia Testa, MD, PhDNovember 21, 2013
Year in ReviewGeorge Yohrling, Ph.D.January, 22, 2014
Silencing Mutant Huntingtin as a Therapy for HDNeil Aronin, MD (University of Massachusetts Medical School)March 27, 2014
Mind the Gap: Thinking Big to Bridge Drug Development in Huntington’s DiseaseDavid Howland, Ph.D.May 22, 2014
Using mouse models to gain therapeutic insights for Huntington’s diseaseWilliam Yang, MD, PhD (UCLA)August 21, 201
Allele-specific silencing of mutant huntingtin gene with ASOsDr. Amber Southwell (University of British Columbia)September 24, 2014
Stem Cell Approaches for HDDr. Vicki Wheelock and Dr. Jan Nolta (UC-Davis)October 7, 2014
2014: The Year in Review for HD ResearchGeorge Yohrling, PhDJanuary 21, 2015
Pride- HD: a dose finding, safety and efficacy study of pridopidine in HD patientsDr. Michael HaydenFebruary 10, 2015
The spread of mutant huntingtin protein from cell to cell and its implications for transplant therapies for Huntington’s diseaseFrancesca Cicchetti, PhDApril 16, 2015